RxDoctor Payments Data

Jennifer Serventi, PA

Physician Assistant · Rochester, NYNPI 1275759052

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $107,215 of the $160,003 with a category attached, or 67.0%. Novocure Inc. accounts for 76.6% of it on its own, with 2 other manufacturers making up the rest. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$160,003in general payments, 2019–2025

Across 427 payments — averaging $374.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$122K
  • Servier Pharmaceuticals LLC$37K
  • Telix Pharmaceuticals$371

What the payments were for

  • Consulting fees$4,3623%
  • Speaking & faculty fees$107,21567%
  • Travel & lodging$39,71625%
  • Food & beverage$8,7115%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novocure Inc.334$122,489
Servier Pharmaceuticals LLC89$37,143
Telix Pharmaceuticals4$371

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,003 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$7,921
Medicare patients
42
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib17$510,153
KoselugoSelumetinib Sulfate34$352,572
ImbruvicaIbrutinib12$277,044
Levetiracetam188$4,591
Lacosamide77$4,301
Granisetron Hcl51$1,650
Gabapentin84$1,407
Dexamethasone70$1,099
Lamotrigine32$932
Oxcarbazepine17$553
Mirtazapine27$365
Oxycodone Hcl17$348
Clonazepam12$295
Methylphenidate Hcl18$281
Carbidopa-LevodopaCarbidopa/Levodopa17$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Servier Pharmaceuticals LLCTibsovo$37,143$510,15317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →